Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial).

Next Previous
Trial Profile

Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease: A Bi-Center, Placebo-Controlled Study (The REST Fatigue Trial).

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Jun 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms REST

Most Recent Events

  • 25 Apr 2015 Results of reanalysis showing significant changes presented at the 67th Annual Meeting of the American Academy of Neurology.
  • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
  • 01 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top